Join the Tagrisso group to help and get support from people like you.
Tagrisso News
ASCO: Osimertinib Improves Progression-Free Survival in EGFR-Mutated Lung Cancer
WEDNESDAY, June 5, 2024 – For patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC), treatment with osimertinib results in significantly longer progression-free...
Tagrisso With the Addition of Chemotherapy Approved in the US for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
19 February 2024 – AstraZeneca’s Tagrisso has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) n...
Osimertinib + Chemo Improves Progression-Free Survival in Advanced NSCLC
THURSDAY, Nov. 16, 2023 – For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS)...
Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
21 December 2020 – AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non...
FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
18 April 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell...
Tagrisso (osimertinib) Receives FDA Full Approval
31 March 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients...
FDA Approves Tagrisso (osimertinib) for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now...
Ask a question
To post your own question to this support group, sign in or create an account.